The Experts below are selected from a list of 93 Experts worldwide ranked by ideXlab platform
Ingo Wilhelm Husstedt - One of the best experts on this subject based on the ideXlab platform.
-
A retrospective long-term analysis of the epidemiology and features of Drug-Induced Headache
Journal of Neurology, 1999Co-Authors: S Evers, Birgit Suhr, Birgit Bauer, Karl-heinz Grotemeyer, Ingo Wilhelm HusstedtAbstract:Drug-Induced Headache is well known to resul from the abuse of compounds taken for the treatment of primary Headache. The features of Drug-Induced Headache depend on various features including the availability of Drugs, the regional health system, and psychogenic factors of the patients. We performed a retrospective study on a series of 257 consecutive German patients presenting with Drug-Induced Headache during the period 1983–1996. Our aim study was to evaluate the demographic features, the frequency of various Drugs used, in particular of ergotamine derivates, and changes in these features during the study period. The frequency of Drug-Induced Headache among all Headache patients was 8%, with a female preponderance of 81%. Drug-Induced Headache occurred in all age groups, predominantly in migraine patients (35%). The mean number of substances used was 2.7, mainly, acetaminophen (47.9%), ergotamine tartrate (45%), and combined analgesics (56%). We did not find a significant difference between the associations with ergotamine tartrate and dihydroergotamine, although the latter was taken less frequently. Comparing the early and late years of our study period, there were no changes in the frequency of Drug-Induced Headache (8% versus 7%), although changes in the frequency of some Drugs changed (barbiturates, ergotamine tartrate, and codeine intake decreased whereas nonsteroidal anti-inflationary Drugs, combined analgesics, and sumatriptan intake increased). Our data suggest that changes in Drug availability and the introduction of classification criteria and treatment recommendations did not have a major impact on the frequency of Drug-Induced Headache.
-
sumatriptan and ergotamine overuse and Drug Induced Headache a clinicoepidemiologic study
Clinical Neuropharmacology, 1999Co-Authors: S Evers, I Gralow, B Suhr, Andre Buchheister, Ingo Wilhelm Husstedt, B. Bauer, E. Bernd RingelsteinAbstract:: Drug-Induced Headache, particularly ergotamine-Induced Headache, is a common problem in migraine treatment. Some case reports suggest that even the new serotonergic antimigraine Drugs such as sumatriptan can lead to overuse and subsequent Drug-Induced Headache. We performed a controlled study to identify the rate of sumatriptan overuse and sumatriptan-Induced Headache and compared it to the rate of ergotamine overuse and ergotamine-Induced Headache. Two thousand sixty-five consecutive heachache patients, all experienced in intake of sumatriptan (n = 631) or ergotamine (n = 620), were enrolled over a three-year study period. The rates of overuse and Drug-Induced Headache and the clinical features of the subgroups were compared. Risk factors for sumatriptan overuse were identified. The rates of ergotamine and sumatriptan overuse were 14.2% and 3.5%, respectively (p < 0.001). Drug-Induced Headache could be found more frequently in cases of ergotamine overuse than in cases of sumatriptan overuse (68% versus 32%; p < 0.01). Development of sumatriptan overuse was most common in patients with previous Drug-Induced Headache (68%), combined Headache as the primary Headache type (45%), and subcutaneous application of sumatriptan (45%). We conclude that sumatriptan intake can lead to overuse and subsequent Drug-Induced Headache. The risk for overuse and Drug-Induced Headache is significantly lower than in patients with ergotamine intake. This might be caused in part by the relatively short period of sumatriptan availability on the market. The new generation of serotonin-1B/D-receptor agonists in the treatment of Headache should have a potential for overuse similar to that of traditional Headache Drugs.
-
Drug Induced Headache long term results of stationary versus ambulatory withdrawal therapy
Cephalalgia, 1999Co-Authors: B Suhr, I Gralow, S Evers, B. Bauer, K H Grotemeyer, Ingo Wilhelm HusstedtAbstract:Drug-Induced Headache is a well-known complication of the treatment of primary Headache disorders, and its successful management is only possible by withdrawal therapy. However, it is unknown whether ambulatory or stationary withdrawal is the therapy preferred. We conducted a prospective study on the outcome of stationary versus ambulatory withdrawal therapy in patients with Drug-Induced Headache according to the International Headache Society criteria. Out of 257 patients with the diagnosis of Drug-Induced Headache during the study period, 101 patients (41 after ambulatory and 60 after stationary withdrawal therapy) could be followed up for 5.9 ± 4.0 years. The total relapse rate after successful withdrawal therapy was 20.8% (14.6% after ambulatory and 25.0% after stationary withdrawal therapy, p <0.2). The main risk factors for a relapse were male sex (OR=3.9, CI=1.3-11.6), intake of combined analgesic Drugs (OR=3.8, CI=1.4-10.3), administration of naturopathy (OR=6.0, CI=1.2-29.3), and a trend to tensi...
-
Drug Induced Headache long term results of stationary versus ambulatory withdrawal therapy
Cephalalgia, 1999Co-Authors: B Suhr, I Gralow, B. Bauer, K H Grotemeyer, Stefan Evers, Ingo Wilhelm HusstedtAbstract:Drug-Induced Headache is a well-known complication of the treatment of primary Headache disorders, and its successful management is only possible by withdrawal therapy. However, it is unknown wheth...
-
peripheral autonomic potentials in primary Headache and Drug Induced Headache
Cephalalgia, 1998Co-Authors: Stefan Evers, B. Bauer, Heike Voss, Peter Soros, Ingo Wilhelm HusstedtAbstract:Autonomic functions of different primary Headache types have been investigated in several studies, most of them analyzing cardiovascular reflex mechanisms or biochemical changes. The results are contradictory; only in tension-type Headache and in cluster Headache has a sympathetic hypofunction been shown in a preponderance of studies. We analyzed the peripheral autonomous potentials (PAPs) in different primary Headache types and in Drug-Induced Headache and compared the results with those of healthy subjects and of patients with low back pain. Latencies of PAPs were significantly increased in all Headache types but not in low back pain; amplitudes of PAPs did not show significant differences compared to healthy subjects. Patients with a long duration of Drug abuse had increased PAP latencies, whereas patients with a high number of migraine attacks per year had decreased latencies. Our data suggest that sympathetic hypofunction as measured by PAP latencies is a general phenomenon in Headache but not in all pain syndromes. Drug abuse leads to an increase of this hypofunction. While measuring PAPs is not an appropriate method by which to differentiate between Headache disorders, it allows assessment of autonomic disturbances in primary and Drug-Induced Headache.
B Suhr - One of the best experts on this subject based on the ideXlab platform.
-
sumatriptan and ergotamine overuse and Drug Induced Headache a clinicoepidemiologic study
Clinical Neuropharmacology, 1999Co-Authors: S Evers, I Gralow, B Suhr, Andre Buchheister, Ingo Wilhelm Husstedt, B. Bauer, E. Bernd RingelsteinAbstract:: Drug-Induced Headache, particularly ergotamine-Induced Headache, is a common problem in migraine treatment. Some case reports suggest that even the new serotonergic antimigraine Drugs such as sumatriptan can lead to overuse and subsequent Drug-Induced Headache. We performed a controlled study to identify the rate of sumatriptan overuse and sumatriptan-Induced Headache and compared it to the rate of ergotamine overuse and ergotamine-Induced Headache. Two thousand sixty-five consecutive heachache patients, all experienced in intake of sumatriptan (n = 631) or ergotamine (n = 620), were enrolled over a three-year study period. The rates of overuse and Drug-Induced Headache and the clinical features of the subgroups were compared. Risk factors for sumatriptan overuse were identified. The rates of ergotamine and sumatriptan overuse were 14.2% and 3.5%, respectively (p < 0.001). Drug-Induced Headache could be found more frequently in cases of ergotamine overuse than in cases of sumatriptan overuse (68% versus 32%; p < 0.01). Development of sumatriptan overuse was most common in patients with previous Drug-Induced Headache (68%), combined Headache as the primary Headache type (45%), and subcutaneous application of sumatriptan (45%). We conclude that sumatriptan intake can lead to overuse and subsequent Drug-Induced Headache. The risk for overuse and Drug-Induced Headache is significantly lower than in patients with ergotamine intake. This might be caused in part by the relatively short period of sumatriptan availability on the market. The new generation of serotonin-1B/D-receptor agonists in the treatment of Headache should have a potential for overuse similar to that of traditional Headache Drugs.
-
Drug Induced Headache long term results of stationary versus ambulatory withdrawal therapy
Cephalalgia, 1999Co-Authors: B Suhr, I Gralow, S Evers, B. Bauer, K H Grotemeyer, Ingo Wilhelm HusstedtAbstract:Drug-Induced Headache is a well-known complication of the treatment of primary Headache disorders, and its successful management is only possible by withdrawal therapy. However, it is unknown whether ambulatory or stationary withdrawal is the therapy preferred. We conducted a prospective study on the outcome of stationary versus ambulatory withdrawal therapy in patients with Drug-Induced Headache according to the International Headache Society criteria. Out of 257 patients with the diagnosis of Drug-Induced Headache during the study period, 101 patients (41 after ambulatory and 60 after stationary withdrawal therapy) could be followed up for 5.9 ± 4.0 years. The total relapse rate after successful withdrawal therapy was 20.8% (14.6% after ambulatory and 25.0% after stationary withdrawal therapy, p <0.2). The main risk factors for a relapse were male sex (OR=3.9, CI=1.3-11.6), intake of combined analgesic Drugs (OR=3.8, CI=1.4-10.3), administration of naturopathy (OR=6.0, CI=1.2-29.3), and a trend to tensi...
-
Drug Induced Headache long term results of stationary versus ambulatory withdrawal therapy
Cephalalgia, 1999Co-Authors: B Suhr, I Gralow, B. Bauer, K H Grotemeyer, Stefan Evers, Ingo Wilhelm HusstedtAbstract:Drug-Induced Headache is a well-known complication of the treatment of primary Headache disorders, and its successful management is only possible by withdrawal therapy. However, it is unknown wheth...
B. Bauer - One of the best experts on this subject based on the ideXlab platform.
-
sumatriptan and ergotamine overuse and Drug Induced Headache a clinicoepidemiologic study
Clinical Neuropharmacology, 1999Co-Authors: S Evers, I Gralow, B Suhr, Andre Buchheister, Ingo Wilhelm Husstedt, B. Bauer, E. Bernd RingelsteinAbstract:: Drug-Induced Headache, particularly ergotamine-Induced Headache, is a common problem in migraine treatment. Some case reports suggest that even the new serotonergic antimigraine Drugs such as sumatriptan can lead to overuse and subsequent Drug-Induced Headache. We performed a controlled study to identify the rate of sumatriptan overuse and sumatriptan-Induced Headache and compared it to the rate of ergotamine overuse and ergotamine-Induced Headache. Two thousand sixty-five consecutive heachache patients, all experienced in intake of sumatriptan (n = 631) or ergotamine (n = 620), were enrolled over a three-year study period. The rates of overuse and Drug-Induced Headache and the clinical features of the subgroups were compared. Risk factors for sumatriptan overuse were identified. The rates of ergotamine and sumatriptan overuse were 14.2% and 3.5%, respectively (p < 0.001). Drug-Induced Headache could be found more frequently in cases of ergotamine overuse than in cases of sumatriptan overuse (68% versus 32%; p < 0.01). Development of sumatriptan overuse was most common in patients with previous Drug-Induced Headache (68%), combined Headache as the primary Headache type (45%), and subcutaneous application of sumatriptan (45%). We conclude that sumatriptan intake can lead to overuse and subsequent Drug-Induced Headache. The risk for overuse and Drug-Induced Headache is significantly lower than in patients with ergotamine intake. This might be caused in part by the relatively short period of sumatriptan availability on the market. The new generation of serotonin-1B/D-receptor agonists in the treatment of Headache should have a potential for overuse similar to that of traditional Headache Drugs.
-
Drug Induced Headache long term results of stationary versus ambulatory withdrawal therapy
Cephalalgia, 1999Co-Authors: B Suhr, I Gralow, S Evers, B. Bauer, K H Grotemeyer, Ingo Wilhelm HusstedtAbstract:Drug-Induced Headache is a well-known complication of the treatment of primary Headache disorders, and its successful management is only possible by withdrawal therapy. However, it is unknown whether ambulatory or stationary withdrawal is the therapy preferred. We conducted a prospective study on the outcome of stationary versus ambulatory withdrawal therapy in patients with Drug-Induced Headache according to the International Headache Society criteria. Out of 257 patients with the diagnosis of Drug-Induced Headache during the study period, 101 patients (41 after ambulatory and 60 after stationary withdrawal therapy) could be followed up for 5.9 ± 4.0 years. The total relapse rate after successful withdrawal therapy was 20.8% (14.6% after ambulatory and 25.0% after stationary withdrawal therapy, p <0.2). The main risk factors for a relapse were male sex (OR=3.9, CI=1.3-11.6), intake of combined analgesic Drugs (OR=3.8, CI=1.4-10.3), administration of naturopathy (OR=6.0, CI=1.2-29.3), and a trend to tensi...
-
Drug Induced Headache long term results of stationary versus ambulatory withdrawal therapy
Cephalalgia, 1999Co-Authors: B Suhr, I Gralow, B. Bauer, K H Grotemeyer, Stefan Evers, Ingo Wilhelm HusstedtAbstract:Drug-Induced Headache is a well-known complication of the treatment of primary Headache disorders, and its successful management is only possible by withdrawal therapy. However, it is unknown wheth...
-
peripheral autonomic potentials in primary Headache and Drug Induced Headache
Cephalalgia, 1998Co-Authors: Stefan Evers, B. Bauer, Heike Voss, Peter Soros, Ingo Wilhelm HusstedtAbstract:Autonomic functions of different primary Headache types have been investigated in several studies, most of them analyzing cardiovascular reflex mechanisms or biochemical changes. The results are contradictory; only in tension-type Headache and in cluster Headache has a sympathetic hypofunction been shown in a preponderance of studies. We analyzed the peripheral autonomous potentials (PAPs) in different primary Headache types and in Drug-Induced Headache and compared the results with those of healthy subjects and of patients with low back pain. Latencies of PAPs were significantly increased in all Headache types but not in low back pain; amplitudes of PAPs did not show significant differences compared to healthy subjects. Patients with a long duration of Drug abuse had increased PAP latencies, whereas patients with a high number of migraine attacks per year had decreased latencies. Our data suggest that sympathetic hypofunction as measured by PAP latencies is a general phenomenon in Headache but not in all pain syndromes. Drug abuse leads to an increase of this hypofunction. While measuring PAPs is not an appropriate method by which to differentiate between Headache disorders, it allows assessment of autonomic disturbances in primary and Drug-Induced Headache.
I Gralow - One of the best experts on this subject based on the ideXlab platform.
-
sumatriptan and ergotamine overuse and Drug Induced Headache a clinicoepidemiologic study
Clinical Neuropharmacology, 1999Co-Authors: S Evers, I Gralow, B Suhr, Andre Buchheister, Ingo Wilhelm Husstedt, B. Bauer, E. Bernd RingelsteinAbstract:: Drug-Induced Headache, particularly ergotamine-Induced Headache, is a common problem in migraine treatment. Some case reports suggest that even the new serotonergic antimigraine Drugs such as sumatriptan can lead to overuse and subsequent Drug-Induced Headache. We performed a controlled study to identify the rate of sumatriptan overuse and sumatriptan-Induced Headache and compared it to the rate of ergotamine overuse and ergotamine-Induced Headache. Two thousand sixty-five consecutive heachache patients, all experienced in intake of sumatriptan (n = 631) or ergotamine (n = 620), were enrolled over a three-year study period. The rates of overuse and Drug-Induced Headache and the clinical features of the subgroups were compared. Risk factors for sumatriptan overuse were identified. The rates of ergotamine and sumatriptan overuse were 14.2% and 3.5%, respectively (p < 0.001). Drug-Induced Headache could be found more frequently in cases of ergotamine overuse than in cases of sumatriptan overuse (68% versus 32%; p < 0.01). Development of sumatriptan overuse was most common in patients with previous Drug-Induced Headache (68%), combined Headache as the primary Headache type (45%), and subcutaneous application of sumatriptan (45%). We conclude that sumatriptan intake can lead to overuse and subsequent Drug-Induced Headache. The risk for overuse and Drug-Induced Headache is significantly lower than in patients with ergotamine intake. This might be caused in part by the relatively short period of sumatriptan availability on the market. The new generation of serotonin-1B/D-receptor agonists in the treatment of Headache should have a potential for overuse similar to that of traditional Headache Drugs.
-
Drug Induced Headache long term results of stationary versus ambulatory withdrawal therapy
Cephalalgia, 1999Co-Authors: B Suhr, I Gralow, S Evers, B. Bauer, K H Grotemeyer, Ingo Wilhelm HusstedtAbstract:Drug-Induced Headache is a well-known complication of the treatment of primary Headache disorders, and its successful management is only possible by withdrawal therapy. However, it is unknown whether ambulatory or stationary withdrawal is the therapy preferred. We conducted a prospective study on the outcome of stationary versus ambulatory withdrawal therapy in patients with Drug-Induced Headache according to the International Headache Society criteria. Out of 257 patients with the diagnosis of Drug-Induced Headache during the study period, 101 patients (41 after ambulatory and 60 after stationary withdrawal therapy) could be followed up for 5.9 ± 4.0 years. The total relapse rate after successful withdrawal therapy was 20.8% (14.6% after ambulatory and 25.0% after stationary withdrawal therapy, p <0.2). The main risk factors for a relapse were male sex (OR=3.9, CI=1.3-11.6), intake of combined analgesic Drugs (OR=3.8, CI=1.4-10.3), administration of naturopathy (OR=6.0, CI=1.2-29.3), and a trend to tensi...
-
Drug Induced Headache long term results of stationary versus ambulatory withdrawal therapy
Cephalalgia, 1999Co-Authors: B Suhr, I Gralow, B. Bauer, K H Grotemeyer, Stefan Evers, Ingo Wilhelm HusstedtAbstract:Drug-Induced Headache is a well-known complication of the treatment of primary Headache disorders, and its successful management is only possible by withdrawal therapy. However, it is unknown wheth...
S Evers - One of the best experts on this subject based on the ideXlab platform.
-
A retrospective long-term analysis of the epidemiology and features of Drug-Induced Headache
Journal of Neurology, 1999Co-Authors: S Evers, Birgit Suhr, Birgit Bauer, Karl-heinz Grotemeyer, Ingo Wilhelm HusstedtAbstract:Drug-Induced Headache is well known to resul from the abuse of compounds taken for the treatment of primary Headache. The features of Drug-Induced Headache depend on various features including the availability of Drugs, the regional health system, and psychogenic factors of the patients. We performed a retrospective study on a series of 257 consecutive German patients presenting with Drug-Induced Headache during the period 1983–1996. Our aim study was to evaluate the demographic features, the frequency of various Drugs used, in particular of ergotamine derivates, and changes in these features during the study period. The frequency of Drug-Induced Headache among all Headache patients was 8%, with a female preponderance of 81%. Drug-Induced Headache occurred in all age groups, predominantly in migraine patients (35%). The mean number of substances used was 2.7, mainly, acetaminophen (47.9%), ergotamine tartrate (45%), and combined analgesics (56%). We did not find a significant difference between the associations with ergotamine tartrate and dihydroergotamine, although the latter was taken less frequently. Comparing the early and late years of our study period, there were no changes in the frequency of Drug-Induced Headache (8% versus 7%), although changes in the frequency of some Drugs changed (barbiturates, ergotamine tartrate, and codeine intake decreased whereas nonsteroidal anti-inflationary Drugs, combined analgesics, and sumatriptan intake increased). Our data suggest that changes in Drug availability and the introduction of classification criteria and treatment recommendations did not have a major impact on the frequency of Drug-Induced Headache.
-
sumatriptan and ergotamine overuse and Drug Induced Headache a clinicoepidemiologic study
Clinical Neuropharmacology, 1999Co-Authors: S Evers, I Gralow, B Suhr, Andre Buchheister, Ingo Wilhelm Husstedt, B. Bauer, E. Bernd RingelsteinAbstract:: Drug-Induced Headache, particularly ergotamine-Induced Headache, is a common problem in migraine treatment. Some case reports suggest that even the new serotonergic antimigraine Drugs such as sumatriptan can lead to overuse and subsequent Drug-Induced Headache. We performed a controlled study to identify the rate of sumatriptan overuse and sumatriptan-Induced Headache and compared it to the rate of ergotamine overuse and ergotamine-Induced Headache. Two thousand sixty-five consecutive heachache patients, all experienced in intake of sumatriptan (n = 631) or ergotamine (n = 620), were enrolled over a three-year study period. The rates of overuse and Drug-Induced Headache and the clinical features of the subgroups were compared. Risk factors for sumatriptan overuse were identified. The rates of ergotamine and sumatriptan overuse were 14.2% and 3.5%, respectively (p < 0.001). Drug-Induced Headache could be found more frequently in cases of ergotamine overuse than in cases of sumatriptan overuse (68% versus 32%; p < 0.01). Development of sumatriptan overuse was most common in patients with previous Drug-Induced Headache (68%), combined Headache as the primary Headache type (45%), and subcutaneous application of sumatriptan (45%). We conclude that sumatriptan intake can lead to overuse and subsequent Drug-Induced Headache. The risk for overuse and Drug-Induced Headache is significantly lower than in patients with ergotamine intake. This might be caused in part by the relatively short period of sumatriptan availability on the market. The new generation of serotonin-1B/D-receptor agonists in the treatment of Headache should have a potential for overuse similar to that of traditional Headache Drugs.
-
Drug Induced Headache long term results of stationary versus ambulatory withdrawal therapy
Cephalalgia, 1999Co-Authors: B Suhr, I Gralow, S Evers, B. Bauer, K H Grotemeyer, Ingo Wilhelm HusstedtAbstract:Drug-Induced Headache is a well-known complication of the treatment of primary Headache disorders, and its successful management is only possible by withdrawal therapy. However, it is unknown whether ambulatory or stationary withdrawal is the therapy preferred. We conducted a prospective study on the outcome of stationary versus ambulatory withdrawal therapy in patients with Drug-Induced Headache according to the International Headache Society criteria. Out of 257 patients with the diagnosis of Drug-Induced Headache during the study period, 101 patients (41 after ambulatory and 60 after stationary withdrawal therapy) could be followed up for 5.9 ± 4.0 years. The total relapse rate after successful withdrawal therapy was 20.8% (14.6% after ambulatory and 25.0% after stationary withdrawal therapy, p <0.2). The main risk factors for a relapse were male sex (OR=3.9, CI=1.3-11.6), intake of combined analgesic Drugs (OR=3.8, CI=1.4-10.3), administration of naturopathy (OR=6.0, CI=1.2-29.3), and a trend to tensi...
